Navigation Links
Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan
Date:9/6/2010

air(R) efficacy after 4 months of treatment and the persistence of its therapeutic effect after only one year of treatment (study VO57.07 conducted in Europe), Stallergenes is now preparing filing NDA in Germany. A phase III pediatric study has been launched.

The Stalair(R) r Bet v 1 tablet (birch pollen recombinant allergen) has been the subject of a positive phase IIb/III clinical trial conducted in allergic rhinitis caused by birch pollen. A confirmatory phase III study is currently being prepared with a view to EMA registration.

The ragweed pollen and Japanese cedar pollen tablets are at an early stage of development.

Altogether, the program covers 80% of the epidemiology for all markets.

ABOUT SHIONOGI & CO.,LTD

Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company is the originator of innovative medicines which have been successfully delivered to millions of patients worldwide. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to immunotherapy treatments for the prevention and treatment of allergy-related respiratory diseases, such as allergic rhinoconjunctivitis, rhinitis and asthma.

A pioneer and leader in sublingual immunotherapy treatments, Stallergenes dedicates more than 20% of its turnover, in gross terms, to Research and Development and is actively involved in the development of a new therapeutic class: sublingual
'/>"/>

SOURCE Stallergenes
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. STALLERGENES : Sales Guidance Exceeded : EUR193 Million, up 13%
2. STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe
3. STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial
4. STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations
5. STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
6. Stallergenes : Investor Meeting: Webcast is Available
7. STALLERGENES: 2008: Strong Performance
8. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
9. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
10. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
11. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy ... of donor stem cells for dogs with osteoarthritis. Dr. ... has performed clinical stem cell therapy for 7 years. ... if a single injection of donor stem cells into ... pain and inflammation in the treated joints. , ...
(Date:10/19/2014)... October 19, 2014 The Asia-Pacific ... market in Asia-Pacific with analysis and forecast of ... Asia Pacific Bromine Market report, to get an ... provides a glimpse of the segmentation in the ... tables and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... , , , BETHLEHEM, Pa., ... , (Logo: http://www.newscom.com/cgi-bin/prnh/200 8 1022 / ... two Lehigh Valley healthcare leaders, Good S h epherd Rehabilitation ... nc. (B. Braun), which are combining their knowledge, expertise and innovative technology ...
... , , , TUSTIN, ... today announced that it will release its financial results for the first ... EDT and will host a conference call and webcast to discuss the ... Peregrine,s senior management will discuss financial results for the first ...
... , , SEATTLE, Aug. 27 ... Company will hold an Analyst Day on Thursday, September 24, 2009 beginning ... audio webcast of the presentation will be accessible through the Investor Relations ... to listen to the live webcast, it will be archived on the ...
Cached Biology Technology:Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 2Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 3Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 4Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results 2
(Date:10/22/2014)... BEDFORD, Mass., Oct. 21, 2014 Aware, Inc. (NASDAQ: ... and services, today reported financial results for its third quarter ... quarter of 2014 was $6.0 million, an increase of 40% ... Operating income in the third quarter of 2014 was $4.1 ... 2013. Higher operating income in the current three month period ...
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2
... for spiders, it can be a matter of life or ... potentially cannibalistic females that he is a suitable mate and ... Cincinnati shows that male wolf spiders are "leaving" little to ... mate. To improve the chances of the right message ...
... A new company has been launched to commercialise ... Strathclyde in Glasgow, for tackling bacterial infection and ... Phage Limited has been established to develop products ... prevention of infection and bacterial contamination in medicine, ...
... standard intestinal examination for diagnosing and monitoring Crohn,s disease. It ... with a camera is passed into the large intestine. MRI ... the course of the disease and how it is responding ... the academic world to develop an objective, quantitative method for ...
Cached Biology News:Spiders adjust courtship signals for maximum effect 2Spiders adjust courtship signals for maximum effect 3Spin-out to apply new technology for tackling infection 2Spin-out to apply new technology for tackling infection 3EU grant for better monitoring of Crohn's disease using MRI 2EU grant for better monitoring of Crohn's disease using MRI 3
... kit is for fine-tuning the bombardment conditions ... is recommended when you are first using ... includes 0.25 g each of 0.6 micrometer, ... microcarriers, 100 each of 9 rupture disks, ...
... Tecans fully automated solution for cell ... automation for cell-line maintenance, expansion, harvesting ... system built upon standard, industry proven ... handling configuration capable of both rapid ...
... is based on PI's experience in high-resolution ... a decade. PI Hexapods were originally used ... adjustments over wide ranges in small step ... freedom with 3 m minimum incremental motion ...
... sequencing is the experimental process of determining ... The automated DNA Sequencing is based on ... polymerase, which allows cycle sequencing reactions. The ... in a capillary instrument controlled by a ...
Biology Products: